Please, Signup (Login) to subscribe or trade (demo)
Astrazeneca PLC stock price, AZN
Astrazeneca PLC stock chart:
Astrazeneca PLC close price: 34
Stock price forecast:
DOWN TO -0.82%
Total forecasts: 60
Reached: 5 (8.33%)
Total Win: 0.89 (2.91%)
No results found.
Showing 1-10 of 523 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Astrazeneca PLC latest news:
GSK's new pharma head to join in September after AstraZeneca tussle
LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.
FTSE 100 boosted by AstraZeneca rise
Shares in the pharmaceutical giant are boosted by promising results from a drug trial.
Drug trial results lift AstraZeneca shares
Shares in the pharmaceutical giant climb, boosting the FTSE 100 in early trade.
Pieris Pharma Soars on AstraZeneca Collaboration
Pieris Pharma stock soars 54% on news of $57.5 mln AstraZeneca deal
Pieris Pharmaceuticals Inc. shares surged as much as 54% in premarket trade Wednesday on news of the company's $57.5 million deal with AstraZeneca to develop drugs for respiratory diseases. The deal includes $45 million upfront and $12.5 million in a milestone payment once Pieris begins a phase 1 trial this year for its lead preclinical drug, PRS-060, which is intended for patients with moderate to severe asthma. AstraZeneca will fund all clinical development and commercialization for PRS-060, with Pieris having the option of U.S. co-development and co-commercialization starting in phase 2a clinical trials. The agreement covers four additional therapeutic programs, with Pieris having the option for U.S. co-development and co-commercialization for two of them. Pieris is eligible for up to $2.1 billion in development dependent milestone payments and eventual commercial payments, according to the release. Pieris shares have surged 11.1% over the last three months, compared with a 4.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
UPDATE 1-AstraZeneca hopes to escape drug sales trough in second half
* Focus on pivotal lung cancer trial results due mid-year
(Adds analyst comment, shares, detail on competitors)
AstraZeneca Q1 upbeat on cancer drugs despite Q1 sales drop
Anglo-Swedish drugmaker AstraZeneca says first-quarter revenue fell amid declining sales of cholesterol treatment Crestor, which lost patent protection last year
Atlantic Power CorporationAT
Atlas Resource PartnersARP
Atlas Resource PartnersARP^D
Atlas Resource PartnersARP^E
Atmos Energy CorporationATO
AU Optronics CorpAUO